Nuvo Research Announces FDA Approval of PENNSAID® 2%
Nuvo Research Announces FDA Approval of PENNSAID® 2%
17, 2014 /PRNewswire/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology today announced that the U.S. Food and Drug Administration (FDA) has approved …
Read more on Sacramento Bee
Nuvo Research Announces FDA Approval of PENNSAID(R) 2%
17, 2014 /PRNewswire/ – Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology today announced that the U.S. Food and Drug Administration (FDA) has approved …
Read more on Wall Street Journal
Outside the Hood
This exemption was employed to address emergent situations where the use of low-risk compounding practices would delay drug administration to the patient (ie, cardiopulmonary resuscitation, emergency department, or preparation of diagnostic agents …
Read more on Pharmacy Times
The Medicines Company's CEO Presents at JPMorgan Healthcare Conference …
We felt that was adequate concentrate for us to grow into and we developed three lines of activity, one in acute cardiovascular, one in surgery in perioperative and more recently we have built an infectious disease, acute care business and our main aim …
Read more on Seeking Alpha